Advertisement

Rheumatology International

, Volume 33, Issue 3, pp 793–797 | Cite as

Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases

  • Daiki Nakagomi
  • Kei Ikeda
  • Hironori Kawashima
  • Yoshihisa Kobayashi
  • Akira Suto
  • Hiroshi Nakajima
Short Communication

Abstract

Yellow nail syndrome is an idiopathic condition characterized by a triad consisting of yellow nail, lymphedema, and pulmonary manifestations. Thiol compounds such as D-penicillamine have been reported to be the major cause of drug-induced yellow nail syndrome in patients with rheumatoid arthritis (RA). We recently experienced two Japanese cases with RA who developed yellow nail under treatment with bucillamine, a thiol-containing anti-rheumatic drug developed and approved in Japan. We reviewed the literature for similar cases and identified 36 RA cases with bucillamine-induced yellow nail, mostly in Japanese medical journals. Most of these cases (90.3%) showed improvement of yellow nail after discontinuation of bucillamine, whereas lymphedema and pulmonary manifestations improved only in 30.8 and 35.0% of the patients, respectively.

Keywords

Yellow nail syndrome Bucillamine Thiol Rheumatoid arthritis Lymphedema Pleural effusion 

References

  1. 1.
    Samman PD, White WF (1964) The “yellow nail” syndrome. Br J Dermatol 76:153–157PubMedCrossRefGoogle Scholar
  2. 2.
    Emerson PA (1966) Yellow nails, lymphoedema, and pleural effusions. Thorax 21:247–253PubMedCrossRefGoogle Scholar
  3. 3.
    Maldonado F, Tazelaar HD, Wang CW, Ryu JH (2008) Yellow nail syndrome: analysis of 41 consecutive patients. Chest 134:375–381PubMedCrossRefGoogle Scholar
  4. 4.
    Mattingly PC, Bossingham DH (1979) Yellow nail syndrome in rheumatoid arthritis: report of three cases. Ann Rheum Dis 38:475–478PubMedCrossRefGoogle Scholar
  5. 5.
    Lehuédé G, Toussirot E, Despaux J, Michel F, Wendling D (2002) Yellow nail syndrome associated with thiol compound therapy for rheumatoid arthritis. Two case reports. Joint Bone Spine 69:406–408PubMedCrossRefGoogle Scholar
  6. 6.
    Ichikawa Y, Shimizu H, Arimori S (1991) Yellow nail syndrome and rheumatoid arthritis. Tokai J Exp Clin Med 16:203–209PubMedGoogle Scholar
  7. 7.
    Ishizaki C, Sueki H, Kohsokabe S, Nishida H (1995) Yellow nail induced by bucillamine. Int J Dermatol 34:493–494PubMedCrossRefGoogle Scholar
  8. 8.
    Yamamoto T, Yokozeki H (2007) Yellow nails under bucillamine therapy for rheumatoid arthritis: a report of two cases. Rheumatol Int 27:603–604PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Daiki Nakagomi
    • 1
  • Kei Ikeda
    • 1
  • Hironori Kawashima
    • 1
  • Yoshihisa Kobayashi
    • 1
  • Akira Suto
    • 1
  • Hiroshi Nakajima
    • 1
  1. 1.Department of Allergy and Clinical ImmunologyChiba University HospitalChibaJapan

Personalised recommendations